Blocking the T cell checkpoint inhibitors programmed cell death protein 1 (PD-1) or signaling PD-L1 on cancer cells has demonstrated remarkably durable clinical responses in certain cancers, as it releases T cells from checkpoint inhibition to unleash antitumor activity (4–8). Here, CD274 is linked to cancer.